Literature DB >> 25563870

Living Donor Liver Transplantation in Children: Surgical and Immunological Results in 250 Recipients at Université Catholique de Louvain.

Michael Gurevich1, Vanessa Guy-Viterbo, Magdalena Janssen, Xavier Stephenne, Françoise Smets, Etienne Sokal, Chantal Lefebvre, Jean-Luc Balligand, Thierry Pirotte, Francis Veyckemans, Philippe Clapuyt, Renaud Menten, Dana Dumitriu, Etienne Danse, Laurence Annet, Stephan Clement de Clety, Thierry Detaille, Dominique Latinne, Christine Sempoux, Pierre-François Laterre, Catherine de Magnée, Jan Lerut, Raymond Reding.   

Abstract

OBJECTIVES: To evaluate the outcome of pediatric living donor liver transplantation (LDLT) regarding portal vein (PV) reconstruction, ABO compatibility, and impact of maternal donation on graft acceptance.
BACKGROUND: LDLT and ABO-mismatched transplantation constitute feasible options to alleviate organ shortage in children. Vascular complications of portal hypoplasia in biliary atresia (BA) and acute rejection (AR) are still major concerns in this field.
METHODS: Data from 250 pediatric LDLT recipients, performed at Cliniques Universitaires Saint-Luc between July 1993 and June 2012, were collected retrospectively. Results were analyzed according to ABO matching and PV complications. Uni- and multivariate analyses were performed to study the impact of immunosuppression, sex matching, and maternal donation on AR rate.
RESULTS: Overall, the 10-year patient survival rate was 93.2%. Neither patient or graft loss nor vascular rejection, nor hemolysis, was encountered in the ABO nonidentical patients (n = 58), provided pretransplant levels of relevant isoagglutinins were below 1/16. In BA recipients, the rate of PV complications was lower after portoplasty (4.6%) than after truncal PV anastomosis (9.8%) and to jump graft interposition (26.9%; P = 0.027). In parental donation, maternal grafts were associated with higher 1-year AR-free survival (55.2%) than paternal grafts (39.8%; P = 0.041), but only in BA patients.
CONCLUSIONS: LDLT, including ABO-mismatched transplantation, constitutes a safe and efficient therapy for liver failure in children. In BA patients with PV hypoplasia, portoplasty seems to constitute the best technique for PV reconstruction. Maternal donation might be a protective factor for AR.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25563870     DOI: 10.1097/SLA.0000000000001094

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  11 in total

1.  Immunologic benefits of maternal living donor allografts in pediatric liver transplantation: fewer rejection episodes and no evidence of de novo allosensitization.

Authors:  Arianna Barbetta; Glenda Meeberg; Brittany Rocque; Sarah Barhouma; Carly Weaver; Susan Gilmour; Farah Faytrouni; Orlee Guttman; Shannon Zielsdorf; Kambiz Etesami; Yong Kwon; George Yanni; Patricia Campbell; James Shapiro; Juliet Emamaullee
Journal:  Pediatr Transplant       Date:  2021-11-21

Review 2.  Biliary atresia: Indications and timing of liver transplantation and optimization of pretransplant care.

Authors:  Shikha S Sundaram; Cara L Mack; Amy G Feldman; Ronald J Sokol
Journal:  Liver Transpl       Date:  2017-01       Impact factor: 5.799

Review 3.  Living donor liver transplantation in Europe.

Authors:  Silvio Nadalin; Ivan Capobianco; Fabrizio Panaro; Fabrizio Di Francesco; Roberto Troisi; Mauricio Sainz-Barriga; Paolo Muiesan; Alfred Königsrainer; Giuliano Testa
Journal:  Hepatobiliary Surg Nutr       Date:  2016-04       Impact factor: 7.293

4.  Safety and Tolerance of Donor-Derived Mesenchymal Stem Cells in Pediatric Living-Donor Liver Transplantation: The MYSTEP1 Study.

Authors:  Steffen Hartleif; Michael Schumm; Michaela Döring; Markus Mezger; Peter Lang; Marc H Dahlke; Joachim Riethmüller; Alfred Königsrainer; Rupert Handgretinger; Silvio Nadalin; Ekkehard Sturm
Journal:  Stem Cells Int       Date:  2017-06-27       Impact factor: 5.443

5.  Superior Outcomes and Reduced Wait Times in Pediatric Recipients of Living Donor Liver Transplantation.

Authors:  Mohit Kehar; Rulan S Parekh; Jennifer Stunguris; Maria De Angelis; Krista Van Roestel; Anand Ghanekar; Mark Cattral; Annie Fecteau; Simon Ling; Binita M Kamath; Nicola Jones; Yaron Avitzur; David Grant; Vicky Lee Ng
Journal:  Transplant Direct       Date:  2019-02-27

6.  Pediatric living donor liver transplantation decade progress in Shanghai: Characteristics and risks factors of mortality.

Authors:  Zhi-Ying Pan; Yi-Chen Fan; Xiao-Qiang Wang; Ling-Ke Chen; Qiao-Qun Zou; Tao Zhou; Bi-Jun Qiu; Ye-Feng Lu; Cong-Huan Shen; Wei-Feng Yu; Yi Luo; Dian-San Su
Journal:  World J Gastroenterol       Date:  2020-03-28       Impact factor: 5.742

7.  Sequential Treatment of Biliary Atresia With Kasai Hepatoportoenterostomy and Liver Transplantation: Benefits, Risks, and Outcome in 393 Children.

Authors:  Roberto Tambucci; Catherine de Magnée; Margot Szabo; Aniss Channaoui; Aurore Pire; Vanessa de Meester de Betzenbroeck; Isabelle Scheers; Xavier Stephenne; Françoise Smets; Etienne M Sokal; Raymond Reding
Journal:  Front Pediatr       Date:  2021-07-07       Impact factor: 3.418

8.  Progressive Fibrosis Is Driven by Genetic Predisposition, Allo-immunity, and Inflammation in Pediatric Liver Transplant Recipients.

Authors:  S Varma; J Ambroise; M Komuta; D Latinne; P Baldin; R Reding; F Smets; X Stephenne; E M Sokal
Journal:  EBioMedicine       Date:  2016-06-01       Impact factor: 8.143

Review 9.  Current techniques for AB0-incompatible living donor liver transplantation.

Authors:  Silke Rummler; Astrid Bauschke; Erik Bärthel; Heike Jütte; Katrin Maier; Patrice Ziehm; Christina Malessa; Utz Settmacher
Journal:  World J Transplant       Date:  2016-09-24

10.  Renoportal Anastomosis in Left Lateral Lobe Living Donor Liver Transplantation: A Pediatric Case.

Authors:  Hiroyuki Ogasawara; Chikashi Nakanishi; Shigehito Miyagi; Kazuaki Tokodai; Yasuyuki Hara; Wataru Nakanishi; Koji Miyazawa; Kenji Shimizu; Hiroyuki Kumata; Hitoshi Goto; Masafumi Goto; Michiaki Unno; Takashi Kamei
Journal:  Case Rep Gastroenterol       Date:  2017-09-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.